MX2009006378A - Biomarcadores para cancer. - Google Patents

Biomarcadores para cancer.

Info

Publication number
MX2009006378A
MX2009006378A MX2009006378A MX2009006378A MX2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A MX 2009006378 A MX2009006378 A MX 2009006378A
Authority
MX
Mexico
Prior art keywords
biomarker
cancer biomarkers
peptide
prostate cancer
cancer
Prior art date
Application number
MX2009006378A
Other languages
English (en)
Spanish (es)
Inventor
Hardev Pandha
Richard George Leonard Morgan
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of MX2009006378A publication Critical patent/MX2009006378A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
MX2009006378A 2006-12-19 2007-12-19 Biomarcadores para cancer. MX2009006378A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers

Publications (1)

Publication Number Publication Date
MX2009006378A true MX2009006378A (es) 2009-08-24

Family

ID=39265269

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006378A MX2009006378A (es) 2006-12-19 2007-12-19 Biomarcadores para cancer.

Country Status (19)

Country Link
US (1) US8460882B2 (enExample)
EP (1) EP2115472B1 (enExample)
JP (1) JP5683108B2 (enExample)
CN (1) CN101675341B (enExample)
AU (1) AU2007335999B2 (enExample)
BR (1) BRPI0720371B8 (enExample)
CA (1) CA2671939C (enExample)
CY (1) CY1115178T1 (enExample)
DK (1) DK2115472T3 (enExample)
ES (1) ES2445185T3 (enExample)
GB (2) GB0625321D0 (enExample)
IL (1) IL199241A (enExample)
MX (1) MX2009006378A (enExample)
NZ (1) NZ577548A (enExample)
PL (1) PL2115472T3 (enExample)
PT (1) PT2115472E (enExample)
RU (1) RU2460075C2 (enExample)
SI (1) SI2115472T1 (enExample)
WO (1) WO2008075056A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
RU2012100903A (ru) * 2009-07-13 2013-08-20 Зе Юниверсити Оф Саррей Терапевтические пептиды, полипептиды и последовательности нуклеиновых кислот
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2012152800A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
CN103797120B (zh) * 2011-09-16 2017-04-12 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
WO2013085483A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Targeting en2, pax2, and/or defb1 for treatment of prostate conditions
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
WO2014025961A1 (en) * 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
CN108738329A (zh) * 2015-05-29 2018-11-02 皇家飞利浦有限公司 前列腺癌预后方法
EP3960195B1 (en) * 2015-09-23 2025-01-08 Centre national de la recherche scientifique Engrailed for treatment of amyotrophic lateral sclerosis
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
CN106795496B (zh) * 2016-12-28 2019-01-18 中国科学院广州生物医药与健康研究院 一种获得t细胞的方法及应用
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒
WO2023076036A1 (en) 2021-10-28 2023-05-04 Analiza, Inc. Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000498A1 (en) * 1997-06-27 1999-01-07 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
WO2000023111A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2001263771A1 (en) 2000-05-30 2001-12-11 Danmarks Miljo Undersogelser An assay method and kit for testing biological material for exposure to stress using biomarkers
AU2001276371A1 (en) * 2000-06-30 2002-01-14 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
EP1362122A2 (en) * 2000-09-12 2003-11-19 TransGenetics Incorporated Microarrayed organization of transcription factor target genes
WO2002054936A2 (en) 2000-12-24 2002-07-18 Kohn, Kenneth, I. A method for detecting biomarkers
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
US20020137086A1 (en) * 2001-03-01 2002-09-26 Alexander Olek Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
CA2593546A1 (en) * 2004-12-02 2006-07-06 Epigenomics Ag Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
WO2006089091A2 (en) 2005-02-18 2006-08-24 Memorial Sloan-Kettering Cancer Center Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
US8460882B2 (en) 2013-06-11
CA2671939A1 (en) 2008-06-26
BRPI0720371B8 (pt) 2021-07-27
US20100093558A1 (en) 2010-04-15
WO2008075056A1 (en) 2008-06-26
IL199241A (en) 2014-03-31
RU2460075C2 (ru) 2012-08-27
CA2671939C (en) 2017-10-03
JP2010513901A (ja) 2010-04-30
AU2007335999B2 (en) 2013-09-05
CN101675341B (zh) 2017-08-08
ES2445185T3 (es) 2014-02-28
EP2115472B1 (en) 2013-11-06
RU2009127774A (ru) 2011-01-27
GB0625321D0 (en) 2007-01-24
EP2115472A1 (en) 2009-11-11
GB0719792D0 (en) 2007-11-21
DK2115472T3 (da) 2014-02-10
PL2115472T3 (pl) 2014-05-30
BRPI0720371A2 (pt) 2013-12-31
NZ577548A (en) 2012-03-30
SI2115472T1 (sl) 2014-05-30
BRPI0720371B1 (pt) 2019-05-28
PT2115472E (pt) 2014-02-14
CN101675341A (zh) 2010-03-17
AU2007335999A1 (en) 2008-06-26
CY1115178T1 (el) 2016-12-14
JP5683108B2 (ja) 2015-03-11

Similar Documents

Publication Publication Date Title
BRPI0720371B8 (pt) métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
IL200487A0 (en) Method and apparatus for detecting computer fraud
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
ES2570359T3 (es) Regiones ultraconservadas que codifican ARNnc
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
CO7160023A2 (es) Métodos y aparatos para predecir riesgo de cáncer de próstata y volumen de glándula prostática
IL233098A (en) Methods for detecting cancer and determining prognosis and survival probabilities and ratio based biomarkers for use therein
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
CL2007001623A1 (es) Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo.
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
WO2008128169A8 (en) Sparc and methods of use thereof
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
AR055316A1 (es) Metodos para la identificacion de tumores que responden al tratamiento con inhibidores de dimerizacion de her (hdis)
CR20120298A (es) Antagonistas de il-17a
CR10325A (es) Diagnosticos y tratamientos para tumores
AR055950A1 (es) Tubo de alimentacion mejorado
DK2211180T3 (da) Anvendelse af protein SATB2 som markør til at skelne colorectal cancer fra andre former for cancer
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
UY31105A1 (es) Predicción pronóstica del melanoma
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
MX2016016994A (es) Metodos para tratar, diagnosticar y pronosticar una malignidad hematologica.

Legal Events

Date Code Title Description
FG Grant or registration